Prostate Cancer - Results from #1260

Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol. March 19, 2024

Exploring the relation of active surveillance schedules and prostate cancer mortality. March 19, 2024

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. March 19, 2024

A Randomized Trial Comparing Quality of Life After LDR or HDR Prostate Brachytherapy Boost with Pelvic External Beam Radiation Therapy. March 19, 2024

Clarity’s Theranostic Prostate Cancer Trial Advances to Multi-Dose Phase March 18, 2024

Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany. March 18, 2024

Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era. March 18, 2024

Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer. March 18, 2024

Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07). March 18, 2024

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. March 18, 2024

Multivitamin use after diagnosis and prostate cancer survival among men with nonmetastatic prostate cancer. March 18, 2024

ProtecT trial: What's new after 15 years of follow-up: Re: Hamdy FC and colleagues; N Engl J Med. 2023 Apr 27. March 15, 2024

Robot-assisted vs open retropubic radical prostatectomy: a propensity score-matched comparative analysis based on 15 years and 18,805 patients. March 15, 2024

Demographic and Clinical Factors Associated With Health-Related Quality-of-Life Profiles Among Prostate Cancer Survivors. March 15, 2024

Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE). March 15, 2024

Cancer centers of excellence for the multidisciplinary management of urologic cancers: The intersection between education, research, and healthcare. March 15, 2024

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. March 15, 2024

Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors. March 14, 2024

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer. March 14, 2024

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. March 14, 2024

Page 64 of 1438